引用次数
引用: 97,128
H-指数: 136
I10-指数 : 357
出版物: 680
Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients.
Thomas J. Smith , Nasser Hanna , David Johnson , Sherman Baker
Journal of Oncology Practice 13 ( 12) 780 -783
1
2017
Identification and Functional Characterization of EGFR V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas
Matthew D. Hellmann , Takuo Hayashi , Boris Reva , Helena A. Yu
JCO precision oncology 1 ( 1) 1 -10
9
2017
OncoKB: A Precision Oncology Knowledge Base.
Ahmet Zehir , Michael F. Berger , Barry S. Taylor , Leonard B. Saltz
JCO precision oncology 2017 ( 1) 1 -16
1,450
2017
Specifying the True- and False-Positive Rates in Basket Trials.
Kristen M. Cunanan , Alexia Iasonos , Ronglai Shen , David M. Hyman
JCO precision oncology 1 ( 1) 1 -5
4
2017
Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers
Michael Offin , Romel Somwar , Natasha Rekhtman , Ryma Benayed
JCO Precision Oncology 2 ( 2) 1 -12
33
2018
Harnessing Clinical Sequencing Data for Survival Stratification of Patients with Metastatic Lung Adenocarcinomas.
Ronglai Shen , Axel Martin , Ai Ni , Matthew Hellmann
JCO precision oncology 3 ( 3) 1 -9
10
2019
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.
Michael Offin , Robin Guo , Stephanie L. Wu , Joshua Sabari
JCO precision oncology 3 ( 3) 1 -8
86
2019
Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer.
Ken Suzawa , Michael Offin , Adam J. Schoenfeld , Andrew J. Plodkowski
JCO precision oncology 3 ( 3) 1 -8
15
2019
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
Daniel T. Milton , Gregory J. Riely , Christopher G. Azzoli , Jorge E. Gomez
Cancer 110 ( 3) 599 -605
98
2007
Acquired BRAF fusions as a mechanism of resistance to EGFR therapy.
Morana Vojnic , Christopher Kurzatkowski , Daisuke Kubota , Ken Suzawa
Journal of Clinical Oncology 36 12122 -12122
1
2018
Real-world data (RWD) on tumor response (rwTR) in advanced non-small cell lung cancer (aNSCLC) patients receiving cancer immunotherapy and targeted therapies.
Michael Lu , Natalia Sadetsky , Peter Lambert , Sam Whipple
Journal of Clinical Oncology 36 6578 -6578
1
2018
Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).
Dong-Wan Kim , Shirish M. Gadgeel , Scott N. Gettinger , Gregory J. Riely
Journal of Clinical Oncology 36 ( 15_suppl) 9009 -9009
29
2018
First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC).
Robert Charles Doebele , Gregory J Riely , Alexander I Spira , Leora Horn
Journal of Clinical Oncology 36 ( 15_suppl) 9015 -9015
33
2018
Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.
Benjamin Besse , Benjamin J. Solomon , Enriqueta Felip , Todd Michael Bauer
Journal of Clinical Oncology 36 ( 15_suppl) 9032 -9032
12
2018
RET-rearranged lung cancers: Immunophenotype and response to immunotherapy.
Joshua K. Sabari , Michael David Offin , Stephanie L Wu , Ai Ni
Journal of Clinical Oncology 36 ( 15_suppl) 9034 -9034
14
2018
Frequency of brain metastases and outcomes in patients with HER2-, KRAS-, and EGFR-mutant lung cancers.
Mark G. Kris , Michael David Offin , Daniel L. Feldman , Ai Ni
Journal of Clinical Oncology 36 ( 15_suppl) 9081 -9081
1
2018
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
Helena A. Yu , Adam J. Schoenfeld , Alex Makhnin , Rachel Kim
JAMA Oncology 6 ( 7) 1048 -1054
15
2020
Small cell lung cancer (SCLC) among patients who are never smokers.
Anna M. Varghese , Helena Alexandra Yu , Helen H. Won , Camelia S. Sima
Journal of Clinical Oncology 31 7593 -7593
2
2013
Prospective molecular evaluation of small cell lung cancer (SCLC) utilizing the comprehensive mutation analysis program at Memorial Sloan-Kettering Cancer Center (MSKCC).
Maria Catherine Pietanza , Anna M. Varghese , Helen H. Won , Lu Wang
Journal of Clinical Oncology 31 7600 -7600
2
2013
New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials
William D. Travis , Elisabeth Brambilla , Gregory J. Riely
Journal of Clinical Oncology 31 ( 8) 992 -1001
338
2013